Future studies of GLP-1 resistance in human subjects targeting GLP-1 signaling may reveal whether correcting dysbiosis is a potentially novel strategy for treating NAFLD/NASH. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.